Cite
Hayes AR, Crawford A, Al Riyami K, et al. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2021;106(12):e4903-e4916doi: 10.1210/clinem/dgab588.
Hayes, A. R., Crawford, A., Al Riyami, K., Tang, C., Bomanji, J., Baldeweg, S. E., Wild, D., Morganstein, D., Harry, A., Grozinsky-Glasberg, S., Oleinikov, K., Khoo, B., Caplin, M. E., Nicolas, G. P., & Grossman, A. B. (2021). Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. The Journal of clinical endocrinology and metabolism, 106(12), e4903-e4916. https://doi.org/10.1210/clinem/dgab588
Hayes, Aimee R, et al. "Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy." The Journal of clinical endocrinology and metabolism vol. 106,12 (2021): e4903-e4916. doi: https://doi.org/10.1210/clinem/dgab588
Hayes AR, Crawford A, Al Riyami K, Tang C, Bomanji J, Baldeweg SE, Wild D, Morganstein D, Harry A, Grozinsky-Glasberg S, Oleinikov K, Khoo B, Caplin ME, Nicolas GP, Grossman AB. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. J Clin Endocrinol Metab. 2021 Nov 19;106(12):e4903-e4916. doi: 10.1210/clinem/dgab588. PMID: 34379772.
Copy
Download .nbib